Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
IPO Year: n/a
Exchange: NASDAQ
Website: advaxis.com
15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
10-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d
SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar